Type 1 Diabetes (T1D), an autoimmune disorder marked by insulin deficiency and insulin resistance, poses significant metabolic challenges in adolescents. To address uncertainties regarding adjunctive metformin therapy, a network meta-analysis was conducted to evaluate the dose-dependent effects of metformin combined with insulin on glycemic control, weight, insulin requirements, and safety outcomes in 764 adolescents aged 10–19 years. The study found that metformin 2.0 g/day significantly decreased BMI and lipid improvement (LDL-C) compared with placebo, while 1.0 g/day, 2.0 g/day, and the 60 kg weight-based regimen reduced daily insulin requirements.
Both the 2.0 g/day and 50 kg weight-based regimens also lowered total cholesterol. No significant improvements were observed in HbA1c or triglyceride levels. Across all dosing strategies, metformin exhibited a safety profile comparable to…
